Project Grant R37CA289715
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models that better capture the initiation, progression, and composition of primary human lung tumors. The researchers aim to introduce oncogenic mutations into primary human lung stem and progenitor cells, and then culture them as tumor organoids or xenograft them into immunodeficient mice. This work seeks to...
This $703,410 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University (NYU) School of Medicine to investigate molecular mechanisms underlying the transition from lung adenocarcinoma to squamous cell carcinoma, which can contribute to resistance to KRAS inhibitor therapies. The research aims to identify chromatin regulators that drive this lineage transition, and systematically decouple the...
This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic approaches to treat mucormycosis, a deadly invasive fungal infection. The key research objectives are: Examining the role of the host cell hypoxia-response pathway and the ANGPTL4 protein in the pathogenesis of mucormycosis, and exploring the...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is funding the research project "Investigating the Cell Intrinsic and Extrinsic Mechanisms Governing Lung Cancer Cell Plasticity" at Columbia University. The $194,292 award over the period of Sep 1, 2024 to Aug 31, 2027 will support the investigator's work to quantitatively track cancer cell state transitions and delineate both cell-autonomous and non-cell-autonomous regulators of...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a $128,228 Project Grant to The Trustees of Columbia University in the City of New York. The grant, titled "Inhalable Extracellular Vesicles Engineering for Lung Cancer Treatment," aims to pioneer precision therapeutics for lung cancer by enhancing IL-12-induced immunotherapy and elucidating the mechanisms by which cardiac fibrosis may exacerbate lung cancer....
This $626,893 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the University of Texas MD Anderson Cancer Center will fund research to study the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity. The research aims to: 1) functionally map the cellular and metabolic features of these bacterial microniches within patient tumor tissues, 2) delineate the human cell types harboring intracellular...